Conduit Pharmaceuticals (CDT) Competitors $0.56 0.00 (-0.36%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. MIRA, GLYC, ABVC, NRSN, COCP, PHIO, INAB, CLRB, ME, and MBRXShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include MIRA Pharmaceuticals (MIRA), GlycoMimetics (GLYC), ABVC BioPharma (ABVC), NeuroSense Therapeutics (NRSN), Cocrystal Pharma (COCP), Phio Pharmaceuticals (PHIO), IN8bio (INAB), Cellectar Biosciences (CLRB), 23andMe (ME), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. MIRA Pharmaceuticals GlycoMimetics ABVC BioPharma NeuroSense Therapeutics Cocrystal Pharma Phio Pharmaceuticals IN8bio Cellectar Biosciences 23andMe Moleculin Biotech MIRA Pharmaceuticals (NASDAQ:MIRA) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Does the MarketBeat Community believe in MIRA or CDT? MIRA Pharmaceuticals received 2 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has stronger earnings & valuation, MIRA or CDT? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Conduit Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.52-2.23Conduit PharmaceuticalsN/AN/A-$540K-$39.33-0.01 Which has more risk & volatility, MIRA or CDT? MIRA Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Does the media prefer MIRA or CDT? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 4 mentions for MIRA Pharmaceuticals and 2 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 0.44 beat MIRA Pharmaceuticals' score of 0.40 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment MIRA Pharmaceuticals Neutral Conduit Pharmaceuticals Neutral Do analysts rate MIRA or CDT? MIRA Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,106.90%. Given MIRA Pharmaceuticals' higher probable upside, research analysts clearly believe MIRA Pharmaceuticals is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Do institutionals & insiders hold more shares of MIRA or CDT? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MIRA or CDT more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Conduit Pharmaceuticals N/A N/A -328.67% SummaryMIRA Pharmaceuticals and Conduit Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.72M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.017.4422.4418.48Price / SalesN/A242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book-0.906.516.774.25Net Income-$540,000.00$143.21M$3.22B$248.23M7 Day Performance0.27%3.97%3.09%3.29%1 Month Performance-37.30%0.37%-0.14%2.43%1 Year Performance-99.81%2.59%17.98%5.54% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit Pharmaceuticals0.3334 of 5 stars$0.56-0.4%N/A-99.8%$3.72MN/A-0.013Short Interest ↑MIRAMIRA Pharmaceuticals2.6016 of 5 stars$0.87-7.9%$14.00+1,518.5%+31.8%$14.54MN/A-1.542Short Interest ↓GLYCGlycoMimetics2.1282 of 5 stars$0.22-1.3%N/A-84.8%$14.19M$10,000.00-0.3750Short Interest ↓Gap UpABVCABVC BioPharma1.0953 of 5 stars$0.87+2.1%N/A-26.4%$13.77M$509,788.00-1.0130NRSNNeuroSense Therapeutics1.1331 of 5 stars$1.00-3.2%N/A-24.8%$13.67MN/A-1.5610Short Interest ↓Negative NewsCOCPCocrystal Pharma2.4883 of 5 stars$1.34+1.9%$7.00+424.2%+4.0%$13.58MN/A-0.7210Short Interest ↑Gap UpPHIOPhio Pharmaceuticals2.5669 of 5 stars$2.83+3.7%$4.00+41.3%-67.4%$13.52MN/A-0.2610INABIN8bio3.5967 of 5 stars$0.17+3.3%$6.00+3,510.1%-82.6%$13.51MN/A-0.2220Short Interest ↓News CoverageCLRBCellectar Biosciences1.8161 of 5 stars$0.29-2.9%$12.50+4,207.4%-90.6%$13.37MN/A-0.1710Analyst ForecastNews CoverageGap DownME23andMeN/A$0.50-35.3%N/A-95.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeMBRXMoleculin Biotech3.1695 of 5 stars$0.95+8.6%$6.00+531.4%-79.6%$13.30MN/A0.0020Short Interest ↓Gap Up Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives GlycoMimetics Alternatives ABVC BioPharma Alternatives NeuroSense Therapeutics Alternatives Cocrystal Pharma Alternatives Phio Pharmaceuticals Alternatives IN8bio Alternatives Cellectar Biosciences Alternatives 23andMe Alternatives Moleculin Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts